Zaxby's brings back milkshakes. What flavors are coming? When does half price end?
Zaxby's is bringing milkshakes back to its menu after being gone for seven years. Here's what we know, including how to get them in Georgia:
The milkshakes are already slowly rolling out to stores, with some already selling it. According to the company's Monday news release, they are expected to be nationwide by June.
Zaxby's said, as of this summer, the milkshakes will be on menus permanently. Meaning you don't have to worry about getting them before they are gone.
The milkshakes are hand spun and topped with whipped cream, colorful sprinkles, and a Maraschino cherry. They come in vanilla, chocolate, strawberry, and "Birthday Cake" with flavors of baked cake, buttercream, and French vanilla.
Zaxby's milkshakes typically start at about $5, but now until June 1, they are being sold at half price: $2.50. You don't need to be part of Zaxby's rewards program to get the sale. All milkshakes are available in only small.
Zaxby's online store locator has started marking restaurants with a milkshake icon to identify whether or not they sell the shakes. Currently, they are sold all over Atlanta, Augusta, Athens, and Macon.
Savannah currently only has one selling it at 8040 White Bluff Rd. Columbus has a small handful on Auburn Avenue, Bradley Park Drive, Ingersoll Street, Schomburg Road, and Ruffie Way.
Miguel Legoas is a Deep South Connect Team Reporter for Gannett/USA Today. Find him on X and Instagram @miguelegoas and email at mlegoas@gannett.com.
This article originally appeared on Savannah Morning News: Zaxby's milkshakes: Price, flavors, and Georgia locations selling them
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Fnac Darty: Number of shares and voting rights as of June, 30 2025
By GlobeNewswire Published on July 3, 2025, 20:45 IST Ivry-sur-Seine – France, July 3, 2025 Regulated information INFORMATION ON THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Statement in compliance with article L. 233-8 II of the French commercial code and article 223- 16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des marchés financiers) Stock Market Euronext Paris ISIN Code FR0011476928 Date Total number of shares composing the share capital of the company Total number of gross voting rights Total number of net voting rights (*) June 30, 2025 29,682,146 29,682,146 29,334,151 (*) Net = After deduction of the shares deprived of voting right In accordance with Article 9 of the Company's Articles of Association, any physical or legal person, acting alone or in concert, who comes to hold, or ceases to hold, directly or indirectly, a percentage of the company's capital or voting rights equal to or greater than 3% or any multiple of 1% above 3%, is required to inform the company by registered letter with return receipt requested within the time limit provided for in Article R. 233-1 of the French Commercial Code (i.e., as of today, at the latest before the close of trading on the fourth trading day following the day on which the shareholding threshold is crossed). Under the terms of the twentieth resolution of the General Meeting of 29 May 2015, it was decided not to grant any double voting rights as instituted by law 2014-384 of 29 March 2014. CONTACT ANALYSTS / INVESTORS [email protected] Attachment Number of shares and voting rights as of June, 30 2025 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
2 hours ago
- Business Upturn
Disclosure of the Number of Shares Forming the Capital and of the Total Number of Voting Rights as of 30 June 2025
French public limited company (société anonyme) with a share capital of €1,454,542,075.00 Registered office : 1973, boulevard de la Défense 92000 Nanterre – France 552 037 806 RCS Nanterre DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 30 JUNE 2025 Advertisement Total number of shares 581,816,830 Theoretical number of voting rights (including treasury stock) 581,816,830 Number of voting rights (excluding treasury stock) 559,625,223 This disclosure is on VINCI web site (section: Finance/Investors/Regulatory information/7. Monthly information concerning the total number of voting rights and shares that make up the company's capital) Attachment 2025 06 30 ddv English version Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Wire
3 hours ago
- Business Wire
CARMAT Announces the Initiation of a Call for Public Tenders (Buyers or Investors) as Part of the Receivership Procedure
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the initiation of a call for public tenders (buyers or investors) 1 as part of the receivership procedure 2 opened on July 1, 2025. A notice will be published in 'Les Echos' French newspaper by the judiciary administrator appointed by the Versailles Economic Affairs Court 3 (AJRS – Maître Philippe Jeannerot), on July 4, 2025. The Notice will however be available in the digital version of the newspaper as early as July 3, 2025 in the evening. People interested and willing to take part in the call for public tenders are invited to get in touch with Mr Valentin Laigneau (AJRS): It is reminded that CARMAT's operations carry on during the observation period, and that CARMAT continues to endeavor to provide continuous support to patients who currently benefit from its Aeson® artificial heart. Press releases will continue to be issued regularly as the Company's situation evolves and the proceedings progress. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company is currently placed in receivership (opened on July 1, 2025) and is facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA). 1 « Appel d'Offres (recherche de repreneurs ou d'investisseurs ») 2 « Redressement judiciaire » 3 « Tribunal des Affaires Economiques de Versailles (France) »
